MedTrace Logo

The Letrozole Administration During Luteal Phase

NCT02686151 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-07-20

No results posted yet for this study

Summary

To investigate the effect of letrozole in patients who have high risk of ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval, the incidence of OHSS were calculated between letrozole group and supporting treatment group.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Letrozole

used after oocyte retrieval

DRUG

Polygeline

used after oocyte retrieval

DRUG

Sodium Chloride

used after oocyte retrieval

DRUG

dexamethasone

used after oocyte retrieval

Sponsors & Collaborators

  • The Affiliated Hospital of Inner Mongolia Medical University

    lead OTHER

Principal Investigators

  • Yu Wang, PhD · Inner Mongolia Medical University affiliated Hospital

  • Xiujuan Chen, MD · Inner Mongolia Medical University affiliated Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-31
Primary Completion
2024-03-31
Completion
2024-12-31

Countries

  • China

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02686151 on ClinicalTrials.gov